Bioventus Inc. (BVS)
NASDAQ: BVS · IEX Real-Time Price · USD
7.17
+0.10 (1.41%)
At close: Jul 19, 2024, 4:00 PM
7.18
+0.01 (0.14%)
Pre-market: Jul 22, 2024, 8:51 AM EDT
Bioventus Employees
Bioventus had 970 employees as of December 31, 2023. The number of employees decreased by 150 or -13.39% compared to the previous year.
Employees
970
Change (1Y)
-150
Growth (1Y)
-13.39%
Revenue / Employee
$538,910
Profits / Employee
-$22,320
Market Cap
457.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 970 | -150 | -13.39% |
Dec 31, 2022 | 1,120 | -80 | -6.67% |
Dec 31, 2021 | 1,200 | 500 | 71.43% |
Dec 31, 2020 | 700 | 50 | 7.69% |
Dec 31, 2015 | 650 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Pacific Biosciences of California | 796 |
Nano-X Imaging | 164 |
Voyager Therapeutics | 162 |
Absci | 155 |
MaxCyte | 143 |
EyePoint Pharmaceuticals | 121 |
Theravance Biopharma | 99 |
BVS News
- 2 months ago - Bioventus Reports First Quarter Financial Results - GlobeNewsWire
- 3 months ago - Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 4 months ago - Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 - GlobeNewsWire
- 6 months ago - Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility - GlobeNewsWire
- 6 months ago - Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - GlobeNewsWire
- 7 months ago - BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Wire
- 7 months ago - Bioventus Names Robert Claypoole as President and Chief Executive Officer - GlobeNewsWire